Shedaoenase, a Novel Fibrinogenase from the Venom of Agkistrodon shedaoenthesis Zhao

Hao-Mang JIAO¹, Li-Xia YANG², Bin LU², Yu-Qun WU², and Yuan-Cong ZHOU^{1*}

¹ Institute of Biochemistry and Cell Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai 200031, China; ² Institute of Snakes and Snake Venom, Dalian Shedao Hospital, Dalian 116041, China

Abstract Shedaoenase, a serine protease, was isolated from the venom of *Agkistrodon shedaoenthesis* Zhao with an apparent molecular mass of 36 kDa. It was purified by affinity chromatography on arginine Sepharose 4B column and anion exchange on Mono Q fast protein liquid chromatography. Shedaoenase preferentially cleaved the A α -chain of human fibrinogen and slowly digested the B β -chain. It also showed arginyl esterase activity using N $_{\alpha}$ -benzoyl-*L*-arginine ethyl ester as a substrate, and some synthetic chromogentic substrates, such as Chromozym PL, S-2266, and S-2160, could also be hydrolyzed. The enzyme activity of shedaoenase could be completely inhibited by phenylmethylsulphonylfluoride and could be little inhibited by the chelating reagent EDTA. The N-terminal sequence of shedaoenase was determined, and its full-length cDNA encoding a protein of 238 amino acid residues was cloned by reverse transcription-polymerase chain reaction from the total mRNA extracted from the snake venom gland. The deduced primary sequence of shedaoenase shares significant homology with other snake venom serine proteases.

Key words Agkistrodon shedaoenthesis Zhao; fibrinogenlytic activity; serine protease

Snake venoms, particularly those belonging to Crotalidae and Viperidae, often induce disorder of the blood coagulation system [1]. In this course, the venom proteases play a crucial role. The endogenous substances in plasma involved in the blood coagulation process, namely coagulation factors, are mostly proteins in the form of inactive precursors. Many snake venom proteases, which are generally classified structurally into serine proteases and metalloproteinases [2], can interact with at least one sort of coagulation factor or other protein components in plasma [3], and cleave specific peptide bond(s) in these protein substrates. These substrates include coagulation factor IX (Christmas factor) [4], factor X (Stuart-Prower factor) [5], factor II (prothrombin) [6,7], plasminogen [8,9], protein C [10,11], factor I (fibrinogen) [9,12–25], kininogen [26-31] and factor V (proaccelerin) [32,33]. Of these, the first five proteins are zymogens that can be converted into active enzymes, the last two can be converted into assistant factors, and fibrinogen can be

converted into fibrin clots or fibrin degradation products.

Fibrinogen is a 340 kDa protein which contains two disulfide-linked symmetric half-molecules. Each half contains three chains designated as α , β , and γ with molecular masses of 63 kDa, 56 kDa, and 47 kDa, respectively [34]. Some snake venom proteinases, called thrombin-like enzymes, can hydrolyze the N-terminal end of A α - or/and B β -chain, and release either fibrinopeptide A [12,14–19], fibrinopeptide B [18,20–22] or both [13,23], inducing fibrin clots in a similar way to thrombin. Some other venom proteinases degrade the A α -, B β - or both chains of fibrinogen at the C-terminus without forming fibrin clots, and they are called fibrin(ogen)olytic enzyme or protease with fibrin(ogen)olytic activity [9,24–27,29–31].

Here, we report the purification and characterization of a fibrinogenase. It is a serine protease, and was named shedaoenase from *Agkistrodon shedaoensis* Zhao.

Materials and Methods

DOI: 10.1111/j.1745-7270.2005.00119.x

Received: June 27, 2005 Accepted: August 29, 2005 *Corresponding author: Tel, 86-21-54921273; Fax, 86-21-54921011; E-mail, zhouyc@sunm.shcnc.ac.cn

[©]Institute of Biochemistry and Cell Biology, SIBS, CAS

Materials

The crude venoms of *A. shedaoensis* Zhao and the living snakes were provided by the Institute of Snakes and Snake Venom, Dalian Shedao Hospital (Dalian, China). Arginine Sepharose 4B gel was the product of Pharmacia Biotech. Synthetic chromogenic substrates were purchased from Sigma. *Escherichia coli* DH16B BL21(DE3) and expression vector pET-40b(+) were preserved by our own laboratory. pMD18-T vector, DNA restriction enzymes and T4 DNA ligase were obtained from TaKaRa. Trizol, *Taq* DNA polymerase, the total RNA isolation kit and Moloney murine leukemia virus first-strand cDNA synthesis kit were purchased from Sangon. Other reagents were of analytic grade.

Purification of shedaoenase

Crude venom of *A. shedaoenthesis* Zhao was dissolved in 50 mM Tris-HCl buffer (pH 8.0) and centrifuged at 6000 g for 10 min. The supernatant was applied onto an arginine Sepharose 4B column pre-equilibrated with the same buffer. The column was washed with this buffer of 4 bed volume at a flow rate of 15 ml/h. A large amount of the aforementioned buffer containing 0.2 M NaCl was used, and the latter fraction of the eluted product was dialyzed, lyophilized and further purified by Mono Q on fast protein liquid chromatography (FPLC).

Electrophoresis

Sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) was carried out according to the method of Laemmli [35]. Ten percent polyacrylamide gel was run under reducing conditions and stained with Coomassie brilliant blue R-250.

Determination of the amino acid sequence of N-terminal

Amino acid sequencing was performed on an auto-PE 491 protein sequencer.

$N_{\alpha}\mbox{-}benzoyl\mbox{-}L\mbox{-}arginine ethyl ester (BAEE) activity and inhibitor assay$

The BAEE activity of shedaoenase was determined according to the method of Glazer [36]. Shedaoenase solution of the same concentration was incubated with different inhibitors in the reaction solution of Tris-HCl (50 mM, pH 7.8) at room temperature for 30 min, then the residual BAEE activity was examined. The inhibition ratio of different inhibitors was calculated respectively. Phenylmethylsulfonyl fluoride (PMSF) was dissolved in isopropylalcohol; EDTA and dithiothreitol (DTT) were dissolved in Tris-HCl buffer (50 mM, pH 7.8; containing 0.1 M NaCl).

Amidolytic activity on synthetic chromogenic substrate

The amidolytic activity of the enzyme was measured with a U3010 spectrophotometer (Pharmacia Fine Chemicals, Uppsala, Sweden) in 1 cm path-length plastic cuvette at 25 °C. Chromogenic substrate assays were performed in 0.1 ml Tris-HCl buffer (50 mM, pH 7.8). The chromogenic substrates S-2266 (D-Val-Leu-Arg-pNA), Chromozym PL (N-p-tosyl-Gly-Pro-Lys-pNA), S-2160 (N-benzoyl-Phe-Val-Arg-pNA), Chromozym PK (Nbenzoyl-Pro-Phe-Arg-pNA), Chromozym TH (N-Cbz-Gly-Pro-Arg- pNA) and S-2222 (N-benzoyl-Ile-Glu-Gly-Arg-pNA) were each dissolved at a final concentration of 100 μ M. The reactions were initiated by the addition of shedaoenase (final concentration 3.6 μ g/ml), and the formation of p-nitroanilide (pNA) was monitored continuously at 405 nm. The amount of substrates hydrolyzed was calculated from the absorbance at 405 nm using a molar extinction coefficient of 10,500 M⁻¹·cm⁻¹ for free pNA.

Fibrin(ogen)olytic and fibrinogen clotting activity

The fibrinolytic activity was assayed on the fibrin plates according to the method of Guan *et al.* [37].

The fibrinogenolytic activity was determined by the method of Utaisincharoen *et al.* [31] with modifications. We mixed 0.1 ml of human fibrinogen solution (0.1 M NaCl, 0.01 M CaCl₂, 0.2% human fibrinogen, 50 mM Tris-HCl, pH 7.4) with 0.1 ml shedaoenase solution (50 µg/ml in 50 mM Tris-HCl, pH 7.4) and incubated the mixture at 37 °C. At various time points, 20 µl of the incubation mixture was withdrawn and added to 10 µl of denaturing solution (6 M urea, 4% SDS, 4% β-mercaptoethanol). The samples were reduced and denatured overnight at room temperature and were analyzed by SDS-PAGE (10% acrylamide).

The fibrinogen clotting activity was determined by the method of Jia *et al.* [30] with modifications. We incubated 5.0×10^{-3} mg of shedaoenase with 0.2 ml of 0.6% human fibrinogen solution (0.1 M NaCl, 0.01 M CaCl₂, 50 mM Tris-HCl, pH 7.4) at 37 °C for 4 h. The formation of fibrin clots was monitored.

Western blot

Western blot was performed as Sambrook *et al.* described previously [38]. The antibody of the thrombinlike enzyme from *Agkistrodon actus* was prepared and preserved by our laboratory.

Total RNA extraction and cDNA amplification

The snake was decapitated. The venom glands were removed immediately, frozen in liquid nitrogen, triturated, and quickly suspended in Trizol reagent (Sangon). The extraction of total RNA and the cDNA synthesis were performed according to the manufacturer's protocol (Sangon).

cDNA cloning and sequencing

Two primers were designed based on the N-terminal sequence of shedaoenase and the conserved 3' non-coding region. Primer-upstream was 5'-GCAGTACTATGGT-(ACTG)A(G)T(TCA)GG(ACTG)GG(ACTG)GA(TC)GA-3', primer-downstream was 5'-TTTCTCCTCTT(GA)A-(GC)(CT)(AT)TTTCAAA-3'.

Polymerase chain reaction (PCR) was carried out to amplify cDNA with total cDNA as the template, and it was performed as follows: first five cycles for denaturation at 94 °C for 1 min, anneal at 48 °C for 1 min, elongation at 72 °C 1.5 min; this process was repeated for 30 cycles under the same conditions, except that the annealing temperature was 52 °C. The PCR products were cloned into pMD18-T vector and transform into *E. coli* DH16B.

The nucleotide sequence was analyzed by the dideoxy chain-termination method using RV-M and M13-47

universal primers.

The DNA sequence and deduced amino acid sequence were compared with sequences in the GenBank database using BLASTN and BLASTP.

Results and Discussion

Purification of shedaoenase

Shedaoenase was purified by a two-step method of affinity chromatography on arginine Sepharose 4B and anion exchange on Mono Q FPLC [**Fig. 1(A)**]. Analysis using SDS-PAGE gave a single band. The apparent molecular mass was estimated to be 36 kDa [**Fig. 1(B)**].

Immune cross-reaction with the antibody of the thrombin-like enzyme from *A. actus*

Western blot analysis showed that shedaoenase has positive immune cross-reaction with the antibody of the thrombin-like enzyme from *A. actus*, which is a typical serine protease [**Fig. 1(C**)].

N-terminal sequence of shedaoenase

The first 10 N-terminal amino acid residues of shedaoenase were sequenced to be VVGGDECNIN, which showed high



Fig. 1 Purification of shedaoenase

(A) Mono Q FPLC of shedaoenase. Active fractions after affinity chromatography on arginine Sepharose 4B was dissolved in 20 mM Tris-HCl (pH 7.1) and applied to Mono Q FPLC. The column was washed with the same buffer and eluted with a linear gradient from 0 to 1 M NaCl at a flow rate of 2 ml/min. The arrow represents fractions containing shedaoenase. (B) SDS-PAGE of shedaoenase. Following Mono Q FPLC chromatography, the fraction of the front half of the peak containing shedaoenase was performed on 12% polyacrylamide gel. The left lane is the molecular weight marker. The right lane is shedaoenase. (C) Weston blot analysis of shedaoenase. 1, negative control (a disintegrin-like protein from *Agkistrodon shedaoenthesis* Zhao); 2, shedaoenase; 3, positive control (a thrombin-like enzyme from *Agkistrodon actus*); 4, molecular weight marker.

http://www.abbs.info; www.blackwellpublishing.com/abbs

identity to other venom serine proteases.

Fibrin(ogen)olytic and fibrinogen clotting activity

Shedaoenase showed fibrinolytic activity when applied to fibrin plates (data not shown). The transparence under control conditions in a Petri dish was visualized.

No obvious fibrin clot was observed when shedaoenase was incubated with human fibrinogen solution.

Shedaoenase preferentially cleaved the α -chain of human fibrinogen and slowly digested the β -chain, but had no effect on digesting the γ -chain (**Fig. 2**).



Fig. 2 SDS-PAGE analysis of the human fibrinogen digested by shedaoenase

1-8, 0.1 ml human fibringen solution was incubated with 0.1 ml shedaoenase solution at 37 °C for 0, 2, 4, 8, 16, 32, 64 and 128 min, respectively; 9, molecular weight marker.

BAEE activity and inhibitor assay

Shedaoenase showed obvious arginyl esterase activity on BAEE. This activity could be entirely inhibited by PMSF, a serine protease inhibitor, but almost not inhibit by the chelating reagent EDTA, which indicated that shedaoenase is a serine protease. The reducing agent DTT could inhibit the enzyme activity considerably, which suggested that the disulfide bond is crucial for maintaining enzyme activity (Table 1).

Table 1	Effects of inhibitors on N_{α} -benzoyl-L-arginine ethy
ester activ	ty of shedaoenase

Inhibitor	Concentration (mM)	Residual activity (%)
Control	0	100±0
PMSF	2	0±0
DTT	10	22±2
EDTA	10	97±4
DTT dithiat	hasital DMSE phanylmathylau	Inhanyi fiyarida

DTT, dithiothreitol; PMSF, phenylmethylsulphonyl fluoride.

Amidolytic activity on chromogenic substrate

Synthetic chromogenic substrates were used for the protease assay of shedaoenase (Fig. 3). Shedaoenase preferentially acts on Chromozym PL (N-p-tosyl-Gly-Pro-LyspNA), the substrate of plasmin. Shedaoenase also shows a substrate preference of S-2266 (D-Val-Leu-Arg-pNA, substrate of kallikrein) > S-2160 (N-benzoyl-Phe-Val-ArgpNA, substrate of thrombin, trypsin and reptilase) > Chromozym TH (N-Cbz-Gly-Pro-Arg-pNA, substrate of thrombin) > Chromozym PK (N-benzoyl-Pro-Phe-ArgpNA, substrate of plasma kallikrein). Shedaoenase shows little activity on S-2222 (N-benzoyl-Ile-Glu-Gly-Arg-pNA, substrate of factor Xa). These results suggested that peptides with Lys at the P1 site are probably preferential substrates for shedaoenase than those with Arg at the P1 site.



Comparison of the hydrolyzing activities of shedaoenase Fig. 3 toward synthetic chromogenic substrates

The amidolytic activity of the enzyme was measured with a spectrophotometer (U3010) in 1 cm path-length plastic cuvette at 25 °C. Chromogenic substrate assays were performed in 0.1 ml reaction solution with 50 mM Tris-HCl, pH 7.8.

Furthermore, shedaoenase can hydrolyze fibrinogen without forming fibrin clots and also can degrade fibrin. This resembles the physiological effect of plasmin. This result is in accordance with the assay of amidolytic activity on synthetic chromogenic substrates, which showed that shedaoenase hydrolyzes the substrate of plasmin more potently than the substrate of thrombin.

Cloning and sequence determination of shedaoenase

The full-length of the PCR product of shedaoenase cDNA was approximately 750 bp, which was cloned into pMD18-T vector and sequenced (Fig. 4). The mature protease covered an open reading frame of 714 nucle-

©Institute of Biochemistry and Cell Biology, SIBS, CAS

	GTGATAGGGGGTGATGAATGTAACATAAATGAACATCGTTTCCTTGTAGCCTTATACACC																			
1	V	Ι	G	G	D	Е	С	Ν	Ι	Ν	Е	Н	R	F	L	V	А	L	Y	Т
	TCTAGATTTAGGACTTTGTTCTGCGGTGGGACTTTGATCAACCAGGAATGGGTGCTCACT																			
21	S	R	F	R	Т	L	F	С	G	G	Т	L	T	Ν	Q	Е	W	V	L	Т
	▼																			
	GCTGCACACTGTGACAGGAAAAATTTCCGGATAAAGCTTGGTATTCATAGCAAAAAGGTA																			
41	А	А	Н	С	D	R	К	Ν	F	R	Ι	Κ	L	G	Ι	Н	S	К	Κ	V
	CCA	AAT	GAG	GAT	GAG	CAG	ACA	AGA	GTC	CCA	AAG	GAG	AAG	TTC	TTT	TGT	стс	AGT	AGC	AAA
61	Р	Ν	Е	D	Е	Q	Т	R	V	Р	Κ	Е	Κ	F	F	С	L	S	S	Κ
								•												
81	N	Y	Т	L	W	D	К	D	Ι	М	L	Ι	R	L	D	S	Р	V	К	Ν
	AGTACACACATTGCGCCTTTCAGCTTGCCCTCCAGCCTCCCAGTGTGGGCCTCAGTTTGC																			
101	S	Т	Н	T	А	Р	F	S	L	Р	S	S	Р	Р	S	V	G	S	V	С
	CGTATTATGGGATGGGGCAGAATCTCACCTACTGAAGAGACTTATCCCGATGTCCCTCAT																			
111	R	T	M	G	W	G	R	T	S	Р	Т	Е	Е	Т	Y	Р	D	V	Р	Н
	TGT	GTT	AAC	ATT	AAC	CTA	стс	GAA	TAT	GAG	ATG	TGT	CGA	GTA	CCT	TAC	CCA	GAA	TTT	GGG
141	С	V	Ν	Ι	Ν	L	L	Е	Y	Е	М	С	R	V	Р	Y	Р	Е	F	G
	-											-						∇		
	TTG	CCA	GCG	ACA	AGC	AGA	ACA	TTG	TGT	GCA	GGT	ATC	CTG	GAA	GGA	GGC	AAA	GĂT	ACA	TGT
161	L	Р	A	Т	S	R	Т	L	C	A	G	Т	L	Е	G	G	К	D	Т	C
				-																
	CGG	GGT	GAC	тст	GGG	GGA	ccc	стс	ATC	тбт	ААТ	GGA	СЛА	TTC	CAG	GGC	АТТ	GCA	тст	TGG
181	R	G	D	S	G	G	Р	L	T	С	N	G	0	F	۵	G	T	A	S	W
101	GGA	GAC	GAT	ССТ	тбт	GCO	CAA	CCG	CAT	AAG	ССТ	GCC	ece	TAC	ACC	AAG	GTC	ттс	GAT	CAT
201	G	D	D	P	С.	A	ົດ	P	Н	K	P	A	A	Y	T	K	V	F	D	Н
201	CTT	GAC	тбG	ATC	AAG	AGC	ATT	ATT	GCA	GGA	ААТ	ACA	GAT	GĊG	TCC	тас	ccc	CCG	TGA	AAA
			. 50							0.011			0.11	0.00	100				1 0/1	1
221	- L.	D	W	T	K	S	T	T	A	G	N	T	D	A	S	- C	Р	Р	_	

Fig. 4 The cDNA and deduced amino acid sequence of shedaoenase

Tentative catalytic triad residues, the primary substrate-binding site and the putative glycosylation site are indicated by $\mathbf{\nabla}, \nabla$ and $\mathbf{\Phi}$, respectively.

otides encoding 238 amino acids. This sequence has been submitted to GenBank and its accession number is AAR11859.

The primary structure of shedaoenase has the typical character of the snake venom serine proteases. Based on the sequence similarity to other venom proteases, the reactive sites of the catalytic triad in shedaoenase are presumed to be His⁴³, Asp⁸⁸ and Ser¹⁹⁴, corresponding to those of His⁴⁰, Asp⁸⁴ and Ser¹⁷⁶ in trypsin. The sequences around these three amino acid residues were found to be highly homologous to other serine proteases. Furthermore, most of the snake venom serine proteases belong to the trypsin-like serine protease family. The bottom of the S1 pocket of trypsin-like serine proteinases is highly conserved with an Asp, which forms a canonical ion pair interaction with the positively charged side chain of the P1 residue of the substrate molecule. This Asp is at the position six residues prior to the active serine.

Shedaoenase contains six disulfide bridges, as do most of the snake venom serine proteases. These disulfide bridges are assigned from the sequence similarity with trypsin, as follows: Cys⁷-Cys¹⁴¹, Cys²⁸-Cys⁴⁴, Cys⁷⁶-Cys²³⁶, Cys¹¹⁹-Cys¹⁹⁰, Cys¹⁵¹-Cys¹⁶⁸, and Cys¹⁸⁰-Cys²⁰⁶.

The molecular mass of shedaoenase, based on the deduced amino acid sequence, is approximately 26.4 kDa, whereas the apparent molecular mass according to the result of SDS-PAGE was estimated to be 36 kDa. This discrepancy may be due to the alteration of electrophoresis behavior caused by the oligosaccharide chains linked to shedaoenase. This presumption was corroborated by the sequence analysis. Shedaoenase has two potential N-glycosylation sites at Asn⁸⁰ and Asn¹⁰⁰. The Asn⁸⁰-Tyr⁸¹-Thr⁸² and the Asn¹⁰⁰-Ser¹⁰¹-Thr¹⁰² residues might be the N-X-T(S) motif, known to be a potential N-glycosylation site linked to asparagine.

The sequence of shedaoenase was compared with those of other snake venoms, human plasmin and the B-chain of human α -thrombin. The sequences were aligned to maximize mutual homologies (**Fig. 5**). The order of the snake venom serine proteases is arranged according to the substrate specificity. Some of them show multiple enzyme activities. The proteases from Trocarin to TSV-PA exhibit no action on fibrinogen; those from ancrodB to KN-BJ can clot fibrinogen (venombin A, B or AB can release fibrinopeptide A, B or both, respectively); and those from ACC-C to shedaoenase show fibrin(ogen)olytic activity.

Most of the snake venom serine proteases are very similar to each other in amino acid sequence, which implies that they might have evolved from the same precursor protein and possibly adapted to each target protein of the snake's prey. In spite of their high homology in primary structure and tertiary structure, the snake venom serine proteases show various substrate specificities. This may be due to some refined difference of the structure at the substrate-binding site. Some surface loops surrounding the extended substrate-binding site may contribute to this diversity [39–42].

It was reported that special residues or motifs may play important roles in substrate recognition. For example, D¹⁰¹D¹⁰²E¹⁰³, particularly the D¹⁰², in TSV-PA (the residue serial number in this paragraph has been adjusted to correspond with **Fig. 5**, for reading convenience) is proven to be responsible for plasminogen activation. The point mutation D102V led to 125-fold decrease of plasminogenactivating activity [9,39,42], and F¹⁰⁰PNG¹⁰³ is only present in factor V activators (RVV-V and VLFVA) [32,33]. The sequences aligned in **Fig. 5** show no distinct difference at the single residue site or motif among the fibrinogen clotting enzymes, fibrin(ogen)olytic enzymes and other enzymes. This suggests that the mechanism of fibrinogen recognition is complicated, and is perhaps a process in which many residues are involved.

		10	20	30	40	50) 6	0	70	80	90	
plasmin	: WVCCC	VAHPHSWRW	IONSMATRFR-	MHRCCCTL	ISPROVITAA	ICLERSPI	pssy	KVILCAS-0	EWNLEPHV	OEIEVSRL	LEPTR	: 83
thrombin-B	IVECS	DARUGMSPU	IOMMUFERSPO	RLLCCASL.	ISDRWWLTAAI	CLLYPP	IDENET RAD L	LVRICKESI	TRYERNIE	RISMLERIY	THPRYN	: 91
Trocarin	: IVNCH	DERLGREPH	IOAVIJINEKC-	EVECCETI	LSPIHVLTAA	CINO	TR	SVRETRELI	SWDKIYVH	TRFVPPNYY	YVHON	: 79
VI. WVA	dar reco	RCDINEHDE	IWAINTSSS	TVHCACTL	INO RUUT. TAW	HCDBK	iaiT	RURDEMESE	NT BARDEO	TRUPPERSE	а Ца́лтія————	- 80
TSV-PA	WFGGD	ECNINEHRS	LWULENSNC-	-FLCGGTL	INODWVWTAAI	CDSN		OLLFEWHSE	KILNED EO	TRDPKEKFF	CBMR8	: 78
AngrodB	· WTGGD	RCNTNEHBB	LVALYDSTTR	MELCOOM		HENKIS	Sŭ	VLYLERHRI	SWEEDDEN	RBFPKRK	TRCNB	- 80
ovroxin an	· WIGGD	RCNTNRHBR	LVALYDELSG	TFLCCCTL	INO RHUI, TAO	IONDS	Lia	NTYLCMHME	NWEEDDED	BBYPRSKMF	FRCNS	- 80
hatroxohin	- WIGGD	RCRITNEHDE	I A FMYYSD	PYRCEMTL	INGRIQUATE	HCMBR	RM	RTHILGKHAD	SWAMYDRW	WRADKKKE	CDWRR	. 78
hothrombin	WIGGD	RCDINEHPE	HARMMYSP	OYFORMUL	INORIUTI. TAAI	HCDKT	Y	RTYLCTHT	RSWAMDDRW	TRYPERET	СРМКК	- 78
flewoyohin	· WICCD	RCNTNEHDE	I.WALYDANSP	PRICECTL	INDENUZITAAI	HCDSB		RMRLCAHSE	KWLNED BO	TRMPKEKET	CDMRR	- 80
Contortrix	wwccn	RCNTNEHDE	I WATEMSMP-	-RWCSCTL	TMO RUUT. T & & I	HCDST	DR	OTRUCAUSE	KULNEDEQ KULNEDEQ	TOMORFRET	CDMRR	
hilineohin	· TIGCD	RCNTNEHBE	LVALYDWISC	SFLCCCTL	ING RHUT. TAAI	HCNMS		YTYL CMHMO	SWORDDER	BBADKKKMI	FRCSB	- 80
KM-BJ	TTEED	DCDTMRHDS	LALWRYG	MROCSCTL.	INORMUL.SAAI	HCDCR	R	NTEL CONTRA	ARM DWRURU	RARAMOO		
ACC-C	· WTGGD	RCNTNEHBR	ALWANG		INORIUTAR	HCDBG	iðiái	BTYLCMHN	SWIMEDAL	BBEBERR	GLMTB	
giletovin	TTCCO	RCDRTCHDM	IN A LUHDSRP-	-STMSPWL	INTERNIT TAAT	HORRLO		RTCRCMENT	WWLDCDRO	VEV & AVERC	уратаронул	- 84
Brevinase	WIGGD	RCNTNEHBE	HALIMSER	-воссеть	INREWVLTAA	COMMG		YTYLGMUN	7SWOYDDRO	RRYPEREYE	CLSSB	: 77
T.mucr-FnL	. WIGGD	ECNINEHDE	UWLVWYDD	-YOCCETL	MERUVLTAA	CNC3	Diá	RIYLEWHSE	K V PINKDWO	REMPKERF	ODSSN	: 77
shedaoenas	· WTGGD	RCNTNRHBR	UWA DY TSEFE	TLEGGETT	INGRIGUITAA	HCD BR		RTRLCTHSE	KWPNRD RO	TREPRESE	CLSSR	· 80
Silediffering												
		-										
	100	▼ ₁₁	.0 12	0	130 .	140	150	160	170	180	190	
plasmin	:	RDIA	<mark>L</mark> LK	ISERAVITI	KVIPACLPS:	PNYVV	ADRTECHT	CWCETQG	TFG	AGLLKENQL	PVIENK <mark>VC</mark> NR	: 151
thrombin-B	:W	RENLDRD I A	LMK	LKKPWAFSI	YTHRVCLED:	RET <mark>AA</mark> SLI	QACYKGRVT	COCNLKETO	TANVERGO	PSWLOVVNL	PIVERPVCKD	: 175
Trocarin	: B D	RVAYDYDIA	IIR	MKTRIOFS	NVVPACLPT.	OF AMEVI	MKODSGIVS	GFGRIOFK-	QPT	SNTLKVITV	PYVORHTCML	: 158
VLFVA	:F	PNGRDRD IN	л тв	LERPVENS	HIAPISLPS	9 109	SPRSRORM	GWCKISTT		PDVPHCARI	FIVKHAWCES	: 154
TSV-PA	:K	DDEVDRD IM	IIIB	LDSSVSNS	EHIAPLSLPS:	5p1	SVGSVCRIM	GWGKTIPTH	(BIY	PDVPHCANI	MILDENVCRT	: 152
AncrodB	:P	RTRØGEDIN	IIR	LNSPVNNS	RHIAPLSLPS	NPP	NVGSVCRWM	GWGSIMKYI	DVL	PDEPECANI	NLWNYTVCRE	: 154
ovroxin an	·	FTRUDED	TR	LMRPWRFS	HIEPLSLPS	ypp	SEDSVCRMM	CNCOLTSP	RT L	PDVPHCANI	NLEMYTVCR	: 151
batroxobin	:K	NVITORDIM	LIR	LDRPVKNS	HIAPLSLPS	Nbb	SVGSVCRIM	CWCAITTS	DTY	PDVPHCANI	nlfnntvcre	: 152
bothrombin	:K	NVI TORDIM	LIR	LMRPVKNS	HIAPUSLPS	Vbb	SVGSVCRIM	CWCAITTS	сDТҮ	PDVPHCANI	NL FNN TVC RE	: 152
flavoxobin	:	d evilded in	I.I.K	LDSPVSYS	EHIAPLSLPS:	9pr	SVGSVCRIM	CWCSITPVE	BTF	PDVPHCANI	NUMDVECKP	: 154
Contortrix	:	d evlord im	LIK	LDS RVSNS	EHIAPLSLPS:	spp	SVGSVCEIM	CWCSITPI	VTF	PDVPHCAMI	NLLDDAACQP	: 152
bilineobin	:	F TRODED TH	LIR	LMRPVENSI	EHIAPLSLPS:	8PP	IVGSVCRVH	GWGTITSP	1RTL	PDVPRCWNI	NLENYTVCRG	: 154
KN-BJ	:	YTKWDKD IM	LIR	LDSPVKNS	HIAPUSLPS:	5PI	IVGSVCRIM	GWGTISTSH	KVIL	SDVPHCANI	NLLMYTVCRA	: 151
ACC-C	:	d T TWDKD I M	LIR	LMRPVRNS	HIAPLSLPS	9PP	SVGSVCRIM	GWGTITSP	JA	PDVPHCANI	NILDYNVCQA	: 151
gilatoxin	: CNYVN	TVLMNNDLL	KRELFPMLIK	LDSSWDYN	ERVAPLSLPT	5 p A	SLCAECSVL	CWGTTTPDI	VIL	PDVPVCVNI	EIFNNAVCQV	: : 169
Brevinase	:0	YNQODND IN	LIR	LMRPVRNS	HIAPLSLPS	GPB	SVCSVCRWM	GWGTITSP	IBTY	PDVPHCANI	NILDYEVC RA	: 151
T.mucr-FnL	:T	YTRWNRDIM	LIR	LDRPVRKS.	AHIAPLSLPS:	5PI	SVGSVCRVH	GWGTITSP <mark>(</mark>	1 <mark>ETY</mark>	PDVPHCANI	NLLDY <mark>E</mark> VCRA	: 151
shedaoenas	:	YT <mark>LWDKD IM</mark>	LIR	LDSPVKNS	THIAPFSLPS:	5PP	SVGSVCRIM	GWGRISPT	6 <mark>ет</mark> ү	PDVPHCWNI	nlleyemc rv	: 154
				\bigtriangledown \lor	7							
		200	210	220	230	240) 25	0 2	260	270	280	
plasmin	: YEFLN	G-RVQSTER	CACHLACCT -	DSCQGD:	SGGPLVCFEK	0 KM IL[IGWTSWCLG-	CARPMKPG	YYVR <mark>VS</mark> RFV	TUIEGVMRN	M :	230
thrombin-B	: STRIR	ITDNMF	CACYKPDEGR	RGDACEGD:	SCCPFVMKSP:	F <u>NN</u> RWYQM	IGIVSWCEG-	CD RD GRYGI	YTHVFRLK	KMIOKAIDO	FGE :	259
Trocarin	: SSDFR	IIQNMF	CAGYDTLPQ-	DACQGD:	SCOPHITAYR	DTHFIT	GIISMCEC-	CARKERYCV	YTKVSKFI	PWIKKIMSL	<u> K</u> :	235
VLFVA	: LYRWV	PADSRTL	CAGILOGCK-	DICEGD:	SGGPLICNG	QIQ	ICINSCCEDP	CGORLEPAN	/YTKVFDY <mark>T</mark>	DWIQSIIAG	NTTATCP- :	235
TSV-PA	: OMSWR	QWANTTL	CAGILQGCR-	DTCHFD	SCCPLICNC-	IRC	CIVSWCCHP	CEODGEDCA	7YTKVFDYL	DWINSIIAC	NEDATCPP :	234
AncrodB	: VFPRI	RKKSKII	CAGDLOGRL-	DSCHCD	SCGPLICSE-	REH	GIWYRCPNP	CAUPDRPAI	YTNI FDHI	HWILSIMAG	MATCYP :	234
gyroxin_an	: AYPRM	PTRVL	CACVLEGGI-	DTCMRD	SGGPLICNG	QF0	ICINEMCED D	CAQPDRPG	7YTKVFDYL	DWIQSWIAC	NTTCS :	228
batroxobin	: AYNGL	PARTI	CAGWLQGGI-	DTCCCD:	SGGPLICNG-	QFC	GILSWCSDP	CAEPRKPAI	YTKVFDYL	PWIQSIIAG	NRTATCP- :	231
bothrombin	: AYNGL	PARTI	CAGVIQGGI-	DTCCCD	SCIERING-	QFQ	ICIN SMCSD 5	CAEPRKPAI	YTRVFDYL	PWIQSIIAG	NETATOPP :	232
flavoxobin	: GYPEL	LPEYRTL	CACULOGCU-	DTCCED	SCUPLICNG-	QFQ	GIVSYCCHP	CCQSRKPC	YTRVFDYN	AWIQSIIAC	NTAATCEP :	236
Contortrix	: GYREV	LPEYRTL	CAGILEGGR	DTCNYD:	SCOPLICNG	QPQ	GIVSNGAHP	CGGAPKACI	YTKVFDYN	DWIQSIIAG	NTAATCPP :	234
bilineobin	: VFPRL	PERSRIL	CAGWLEGGI-	DTCKRD:	SCOPLICNC-	QFQ	GIVSWCPKR	CAQPREPAI	YSKVFDEL	DWIQSIIAG	NETWICE - :	235
KN-BJ	AYPEL	PATSRTI	CAGILQGCK-	DTCVGD	HEICPLITCING-	QVO	GIVSWCSDV	CGYVLEPAI	YTRVSDYT	RWINSIIAG	NTTATCPP :	233
ACC-C	: ANKGL	A <u>00</u> 01	CACHLEGER-	DTCKGD	SIGNATIONS-	080	GILSNCCMP	CAUPRKPG	YTRVFDYT	DWIQSIISC	MIDATOPP :	231
gilatoxin	: MRDLW	KFTNKI	CAGWD FGGR-	DSCKGD	SCEPTWCDN-	QLT	envswefn-	CEQCER-Y(MIGLINFN	ROIONIIQG	GINCP :	245
Brevinase	: AYAGL	PATSRTL	EACHIRCER	DSCRED	HERBURG AND -	RT	<u>leit vennee</u> n t	CAUPREPGI	YTROPDYT	DUTUSTIAG	NTTWIND PP :	233
T.mucr-FnL	: AYRGL	eensrti	CACILIKCCK-	DSCVGD	SIGLEPTINE NIC-	0FC	GIVSWGGDP	CAUPREPCI	YY TIMV FDHL	DUTKGTIAG	NUCALCHT :	233
shedaoenas	: PLONEF	GLIPANSISIN		ICHERICO	38899AAAAA		DEDIARMORDING	DESCOUNTER STATE	LINE STORE STORE	DATERSTOLED	MIDDISE099	238

Fig. 5 Comparison of the amino acid sequences of snake venoms and mammalian serine proteases

The sequence of shedaoenase was compared with those of other snake venom, human plasmin and the B-chain of human α -thrombin. The proteases sequences were aligned to maximize mutual homologies. The orders of the snake venom serine proteases are arranged according to the substrate specificity; some of them show multiple enzyme activity. The proteases from Trocarin toTSV-PA exhibit no action on fibrinogen, from ancrodB to KN-BJ can clot fibrinogen (venombin A, B or AB can release fibrinopeptide A, B or both, respectively), from ACC-C to shedaoenase show fibrin(ogen)olytic activity. The tentative catalytic triad residues and the major substrate-binding site are indicated by \checkmark and \bigtriangledown respectively. Pla (plasmin), human plasmin (REFSEQ NM_000301.1); thr (thrombin), human alpha-thrombin (REFSEQ NM_000506.2); Tro (trocarin), prothrombin activator from *Tropidechis carinatus* [6] (SwissProt P81428); VLF (vl-fva), factor V activator from *Vipera lebetina* [32] (SwissProt Q9PT41); TSF (TSV-PA), plasminogen activator from *Trimeresurus stejnege* [8] (SwissProt Q91516); Anc (ancrodB), venombin A from *Agkistrodon rhodostoma* (Malayan pit viper) (*Calloselasma rhodostoma*) [12] (SwissProt P47797); gyr (gyroxin analog), venombin A from *Lachesis m. muta* [17] (SwissProt P33589); bat (batroxobin), venombin A from *Tri. flavoviridis* [16] (SwissProt P04971); bot (bothrombin), venombin A from *Tri. flavoviridis* [16] (SwissProt P05620); Con (Contortrixobin), venombin A from *B. jararaca* [14] SwissProt O13069); Acc (ACC-C), protein C activator from *A. contortrix* contortrix, can also hydrolyze many other substrates and show fibrinogenolytic activity [10] (SwissProt P09872); Gil (gilatoxin), kallikrein-like from *Heloderma horridum* horridum, shows fibrinogenolytic activity (Aa preferentially) [31] (SwissProt P43685); Bre (brevinase), a two-chain fibrinolytic enzyme from Korean snake, *A. blomhoffii* brevicaudus [25] (SwissProt Q9PT51); Truu (T. mucr-FnL), b-fibrinogenase from Taiwan Habu (*Tri. mucrosquamatus*) [26] (Swiss

©Institute of Biochemistry and Cell Biology, SIBS, CAS

References

- 1 Bailey GS. Enzymes from Snake Venom. Fort Collins: Alaken Inc. 1998
- 2 Matsui T, Fujimura Y, Titani K. Snake venom proteases affecting hemostasis and thrombosis. Biochim Biophys Acta 2000, 1477: 146–156
- 3 Francis S. Markland. Snake venoms and the haemostatic system. Toxicon 1998, 36: 1749–1800
- 4 Lindquist PA, Fujikawa K, Davie EW. Activation of bovine factor IX (Christmas factor) by factor XIa (activated plasma thromboplastin antecedent) and a protease from Russell's viper venom. J Biol Chem 1978, 253: 1902–1909
- 5 Kisiel W, Hermodson MA, Davie EW. Factor X activating enzyme from Russell's viper venom: Isolation and characterization. Biochemistry 1976, 15: 4901–4906
- 6 Joseph JS, Chung MC, Jeyaseelan K, Kini RM. Amino acid sequence of trocarin, a prothrombin activator from *Tropidechis carinatus* venom: Its structural similarity to coagulation factor Xa. Blood 1999, 94: 621–631
- 7 Zhang Y, Lee WH, Gao R, Xiong YL, Wang WY, Zhu SW. Effects of Pallas' viper (*Agkistrodon halys* pallas) venom on blood coagulation and characterization of a prothrombin activator. Toxicon 1998, 36: 143–152
- 8 Parry MA, Jacob U, Huber R, Wisner A, Bon CJ, Bode W. The crystal structure of the novel snake venom plasminogen activator TSV-PA: A prototype structure for snake venom serine proteinases. Structure 1998, 6: 1195–1206
- 9 Zhang Y, Wisner A, Xiong Y, Bon C. A novel plasminogen activator from snake venom. Purification, characterization, and molecular cloning. J Biol Chem 1995, 270: 10246–10255
- 10 McMullen BA, Fujikawa K, Kisiel W. Primary structure of a protein C activator from *Agkistrodon contortrix* contortrix venom. Biochemistry 1989, 28: 674–679
- 11 Kisiel W, Kondo S, Smith KJ, McMullen BA, Smith LF. Characterization of a protein C activator from *Agkistrodon contortrix* contortrix venom. J Biol Chem 1987, 262: 12607–12613
- 12 Au LC, Lin SB, Chou JS, Teh GW, Chang KJ, Shih CM. Molecular cloning and sequence analysis of the cDNA for ancrod, a thrombin-like enzyme from the venom of *Calloselasma rhodostoma*. Biochem J 1993, 294: 387–390
- 13 Nikai T, Ohara A, Komori Y, Fox JW, Sugihara H. Primary structure of a coagulant enzyme, bilineobin, from *Agkistrodon bilineatus* venom. Arch Biochem Biophys 1995, 318: 89–96
- 14 Nishida S, Fujimura Y, Miura S, Ozaki Y, Usami Y, Suzuki M, Titani K et al. Purification and characterization of bothrombin, a fibrinogen-clotting serine protease from the venom of *Bothrops jararaca*. Biochemistry 1994, 33: 1843–1849
- 15 Hahn BS, Yang KY, Park EM, Chang IM, Kim YS. Purification and molecular cloning of calobin, a thrombin-like enzyme from *Agkistrodon caliginosus* (Korean viper). J Biochem (Tokyo) 1996, 119: 835–843
- 16 Shieh TC, Kawabata S, Kihara H, Ohno M, Iwanaga S. Amino acid sequence of a coagulant enzyme, flavoxobin, from *Trimeresurus flavoviridis* venom. J Biochem (Tokyo) 1988, 103: 596–605
- 17 Magalhaes A, Da Fonseca BC, Diniz CR, Gilroy J, Richardson M. The complete amino acid sequence of a thrombin-like enzyme/gyroxin analogue from venom of the bushmaster snake (*Lachesis muta* muta). FEBS Lett 1993, 329: 116–120
- 18 Amiconi G, Amoresano A, Boumis G, Brancaccio A, De Cristofaro R, De Pascalis A, Di Girolamo S *et al*. A novel venombin B from *Agkistrodon contortrix* contortrix: Evidence for recognition properties in the surface around the primary specificity pocket different from thrombin. Biochemistry 2000, 39: 10294–10308

- Itoh N, Tanaka N, Funakoshi I, Kawasaki T, Mihashi S, Yamashina I.
 Organization of the gene for batroxobin, a thrombin-like snake venom enzyme.
 Homology with the trypsin/kallikrein gene family. J Biol Chem 1988, 263:
 7628–7631
- 20 Herzig RH, Ratnoff OD, Shainoff JR. Studies on a procoagulant fraction of southern copperhead snake venom: The preferential release of fibrinopeptide B. J Lab Clin Med 1970, 76: 451–465
- 21 Shainoff JR, Welches WR. Studies of the preferential release of fibrinopeptide B by copperhead procoagulant enzyme. In: Pirkle H, Markland FS eds. Hemostasis and Animal Venoms. New York: Marcel Dekker Inc. 1988
- 22 Guan LF, Chi CW, Yuan M. Study on the thrombin-like enzyme preferentially releasing fibrinopeptide B from the snake venom of *Agkistrodon halys* pallas. Thromb Res 1984, 35: 301–310
- 23 Pirkle H, Theodor I, Miyada D, Simmons G. Thrombin-like enzyme from the venom of Bitis gabonica. Purification, properties, and coagulant actions. J Biol Chem 1986, 261: 8830–8835
- 24 Lee JW, Seu JH, Rhee IK, Jin I, Kawamura Y, Park W. Purification and characterization of brevinase, a heterogeneous two-chain fibrinolytic enzyme from the venom of Korean snake, *Agkistrodon blomhoffii* brevicaudus. Biochem Biophys Res Commun 1999, 260: 665–670
- 25 Lee JW, Park W. cDNA cloning of brevinase, a heterogeneous two-chain fibrinolytic enzyme from *Agkistrodon blomhoffii* brevicaudus snake venom, by serial hybridization-polymerase chain reaction. Arch Biochem Biophys 2000, 377: 234–240
- 26 Hung CC, Huang KF, Chiou SH. Characterization of one novel venom protease with beta-fibrinogenase activity from the Taiwan habu (*Trimeresurus mucrosquamatus*): Purification and cDNA sequence analysis. Biochem Biophys Res Commun 1994, 205: 1707–1715
- 27 Hung CC, Chiou SH. Fibrinogenolytic proteases isolated from the snake venom of Taiwan habu: Serine proteases with kallikrein-like and angiotensindegrading activities. Biochem Biophys Res Commun 2001, 281: 1012–1018
- 28 Serrano SM, Hagiwara Y, Murayama N, Higuchi S, Mentele R, Sampaio CA, Camargo AC *et al*. Purification and characterization of a kinin-releasing and fibrinogen-clotting serine proteinase (KN-BJ) from the venom of *Bothrops jararaca*, and molecular cloning and sequence analysis of its cDNA. Eur J Biochem 1998, 251: 845–853
- 29 Felicori LF, Souza CT, Velarde DT, Magalhaes A, Almeida AP, Figueiredo S, Richardson M *et al*. Kallikrein-like proteinase from bushmaster snake venom. Protein Expr Purif 2003, 30: 32–42
- 30 Jia YH, Jin Y, Lu QM, Li DS, Wang WY, Xiong YL. Jerdonase, a novel serine protease with kinin-releasing and fibrinogenolytic activity from *Trimeresurus jerdonii* venom. Acta Biochim Biophys Sin 2003, 35: 689–694
- 31 Utaisincharoen P, Mackessy SP, Miller RA, Tu AT. Complete primary structure and biochemical properties of gilatoxin, a serine protease with kallikrein-like and angiotensin-degrading activities. J Biol Chem 1993, 268: 21975–21983
- 32 Siigur E, Aaspollu A, Siigur J. Molecular cloning and sequence analysis of a cDNA for factor V activating enzyme, a coagulant protein from *Vipera lebetina* snake venom. Biochem Biophys Res Commun 1999, 262: 328–332
- 33 Tokunaga F, Nagasawa K, Tamura S, Miyata T, Iwanaga S, Kisiel W. The factor V-activating enzyme (RVV-V) from Russell's viper venom. Identification of isoproteins RVV-V alpha, -V beta, and -V gamma and their complete amino acid sequences. J Biol Chem 1988, 263: 17471–17481
- 34 Hettasch JM, Greenberg CS. Fibrin formation and stabilization. In: Loscalzo J, Schafer AI eds. Thrombosis and Hemorrhage. Baltimore: Williams & Wilkins 1998
- 35 Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970, 227: 680–685

http://www.abbs.info; www.blackwellpublishing.com/abbs

- 36 Glazer AN. Esteratic reactions catalyzed by subtilisins. J Biol Chem 1967, 242: 433–436
- 37 Guan AL, Retzios AD, Henderson GN, Markland FS Jr. Purification and characterization of a fibrinolytic enzyme from venom of the southern copperhead snake (*Agkistrodon contortrix* contortrix). Arch Biochem Biophys 1991, 289: 197–207
- 38 Sambrook J, Fritsch EF, Maniatis T. Molecular Cloning: A Laboratory Manual. 3rd ed. New York: Cold Spring Harbor Laboratory Press 2001
- 39 Maroun RC. Molecular Basis for the partition of the essential functions of

thrombin among snake venom serine proteinases: The case of thrombin-like enzymes. Haemostasis 2001, 31: 247–256

- 40 Guillin MC, Bezeaud A, Bouton MC, Jandrot-Perrus M. Thrombin specificity. Thromb Haemost 1995, 74: 129–133
- 41 Perona JJ, Craik CS. Structural basis of substrate specificity in the serine proteases. Protein Sci 1995, 4: 337–360
- 42 Zhu ZL, Liang Z, Zhang TY, Zhu ZQ, Xu WH, Teng MK, Niu LW. Crystal structures and amidolytic activities of two glycosylated snake venom serine proteinases. J Biol Chem 2005, 280: 10524–10529

Edited by Zu-Xun GONG